Engineering the proteolytic specificity of activated protein C improves its pharmacological properties

Human activated protein C (APC) is an antithrombotic, antiinflammatory serine protease that plays a central role in vascular homeostasis, and activated recombinant protein C, drotrecogin alfa (activated), has been shown to reduce mortality in patients with severe sepsis. Similar to other serine proteases, functional APC levels are regulated by the serine protease inhibitor family of proteins including α1-antitrypsin and protein C inhibitor. Using APC–substrate modeling, we designed and produced a number of derivatives with the goal of altering the proteolytic specificity of APC such that the variants exhibited resistance to inactivation by protein C inhibitor and α1-antitrypsin yet maintained their primary anticoagulant activity. Substitutions at Leu-194 were of particular interest, because they exhibited 4- to 6-fold reductions in the rate of inactivation in human plasma and substantially increased pharmacokinetic profiles compared with wild-type APC. This was achieved with minimal impairment of the anticoagulant/antithrombotic activity of APC. These data demonstrate the ability to selectively modulate substrate specificity and subsequently affect in vivo performance and suggest therapeutic opportunities for the use of protein C derivatives in disease states with elevated serine protease inhibitor levels.

[1]  B. Dahlbäck,et al.  Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. , 2000, Biochemistry.

[2]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[3]  J. Nishioka,et al.  Protein C inhibitor. Purification from human plasma and characterization. , 1983, The Journal of biological chemistry.

[4]  J. Walls,et al.  Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. , 1991, The Journal of biological chemistry.

[5]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[6]  S Foundling,et al.  The 2.8 A crystal structure of Gla‐domainless activated protein C. , 1996, The EMBO journal.

[7]  R. Bertina,et al.  Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. , 1983, The New England journal of medicine.

[8]  J. Whisstock,et al.  An atlas of serpin conformations. , 1998, Trends in biochemical sciences.

[9]  K. Takatsuki,et al.  Effect of Protein C and Activated Protein C on Coagulation and Fibrinolysis in Normal Human Subjects , 1990, Thrombosis and Haemostasis.

[10]  C. Craik,et al.  Engineering enzyme specificity. , 1998, Current opinion in chemical biology.

[11]  S. Rapaport,et al.  Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. , 1984, The New England journal of medicine.

[12]  B. Keyt,et al.  A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.

[13]  C. Esmon.  The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  C. Esmon,et al.  Molecular basis of residue 192 participation in determination of coagulation protease specificity. , 1996, European journal of biochemistry.

[15]  J. Griffin,et al.  Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. , 1988, The Journal of biological chemistry.

[16]  Greiner Ac,et al.  Schizophrenia-melanosis: cause or side-effect? , 1965 .

[17]  K. Morgan,et al.  Regulation of the serine proteinase inhibitor (SERPIN) gene alpha 1-antitrypsin: a paradigm for other SERPINs. , 1997, The international journal of biochemistry & cell biology.

[18]  J. Katz,et al.  INHERITED PROTEIN C DEFICIENCY AND COUMARIN-RESPONSIVE CHRONIC RELAPSING PURPURA FULMINANS IN A NEWBORN INFANT , 1983, The Lancet.

[19]  D. Mcclure,et al.  High-level expression of secreted proteins from cells adapted to serum-free suspension culture. , 1993, BioTechniques.

[20]  C. Craik,et al.  Evolutionary Divergence of Substrate Specificity within the Chymotrypsin-like Serine Protease Fold* , 1997, The Journal of Biological Chemistry.

[21]  D. Schoepp,et al.  Pharmacological characterization of desensitization in a human mGlulα‐expressing non‐neuronal cell line co‐transfected with a glutamate transporter , 1996, British journal of pharmacology.

[22]  S. Stone,et al.  Interaction of activated protein C with serpins. , 1993, The Biochemical journal.

[23]  D. Foster,et al.  Resistance to inhibition by alpha-1-anti-trypsin and species specificity of a chimeric human/bovine protein C. , 1994, Biochemistry.

[24]  D. Botstein,et al.  A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Mcclure,et al.  E1a-responsive mammalian host/vector system for the stable high-level expression of secreted proteins. , 1992, Nucleic acids research.

[26]  B. Keyt,et al.  A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen , 1993, Thrombosis and Haemostasis.

[27]  A. Rezaie.  Role of Residue 99 at the S2 Subsite of Factor Xa and Activated Protein C in Enzyme Specificity* , 1996, The Journal of Biological Chemistry.

[28]  M. Scully,et al.  Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation , 1993, Thrombosis and Haemostasis.

[29]  K. Takatsuki,et al.  Treatment of patients with disseminated intravascular coagulation by protein C , 1990, American journal of hematology.

[30]  A. Tulinsky,et al.  Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. , 1994, Biochemistry.

[31]  B. Grinnell,et al.  Trans–Activated Expression of Fully Gamma–Carboxylated Recombinant Human Protein C, an Antithrombotic Factor , 1987, Bio/Technology.

[32]  R. Bischoff,et al.  Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. , 1990, The Journal of biological chemistry.

[33]  C. Craik,et al.  Structural basis of substrate specificity in the serine proteases , 1995, Protein science : a publication of the Protein Society.

[34]  R. Huber,et al.  Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. , 1984, Journal of molecular biology.

[35]  W. Rutter,et al.  Redesigning trypsin: alteration of substrate specificity. , 1985, Science.

[36]  J. Magny,et al.  Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. , 1991, The New England journal of medicine.

[37]  L. Gelbert,et al.  Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis* , 2001, The Journal of Biological Chemistry.

[38]  C. Esmon,et al.  The Protein C Pathway: New Insights , 1997, Thrombosis and Haemostasis.

[39]  R. Jackson,et al.  The novel mechanism of initiation of picornavirus RNA translation. , 1990, Trends in biochemical sciences.

[40]  B. Grinnell,et al.  Mutation of Protease Domain Residues Lys37-39 in Human Protein C Inhibits Activation by the Thrombomodulin-Thrombin Complex without Affecting Activation by Free Thrombin* , 1996, The Journal of Biological Chemistry.

[41]  F. Church,et al.  General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[42]  E. Goldsmith,et al.  Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.

[43]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[44]  K. Mann,et al.  The mechanism of inactivation of human factor V and human factor Va by activated protein C. , 1994, The Journal of biological chemistry.

[45]  E. Goldsmith,et al.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.